The University of Texas - MD Anderson Cancer Center
The University of Texas - MD Anderson Cancer Center
Houston, Texas, United States8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Sezary syndrome, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, mycosis fungoides, neoplasm, primary cutaneous T-cell non-Hodgkin lymphoma | Recruiting | Phase 1 | 2026-09-30 | NCT07192471 | |
| Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-15 | NCT05898399 | |
| IBRX-042 In Participants With HPV-Associated Tumors | HPV-Related Carcinoma | Active, not recruiting | Phase 1 | 2026-08-31 | NCT05976828 | |
| Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 | 2026-08-13 | NCT06384352 | |
| A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET | digestive system neuroendocrine neoplasm | Active, not recruiting | Phase 3 | 2026-07-28 | NCT05050942 | |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, bone marrow disorder, hematologic disorder, primary myelofibrosis | Active, not recruiting | Phase 3 | 2026-07-16 | NCT04717414 | |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, beta thalassemia, bone marrow disorder, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, myelodysplastic syndrome, thalassemia | Recruiting | Phase 3 | 2026-07-01 | NCT04064060 | |
| A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | Locally Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-04-17 | NCT06307795 |